Active Not RecruitingNCT04514653
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
PHASE2 · 146 planned enrolment
- Countries listed
- 1
- Registry update
- February 27, 2026
